Lateral Flow Assays Market Research Report by Product (Kits & Reagents and Lateral Flow Readers), Technique, Sample Type, Application, End-User, State (New York, Illinois, and California) - United States Forecast to 2027 - Cumulative Impact of COVID-19

The United States Lateral Flow Assays Market size was estimated at USD 1,231.41 million in 2021 and expected to reach USD 1,282.00 million in 2022, and is projected to grow at a CAGR 5.93% to reach USD 1,740.65 million by 2027.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Lateral Flow Assays to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Product, the market was studied across Kits & Reagents and Lateral Flow Readers. The Lateral Flow Readers is further studied across Benchtop Readers, Digital/Handheld Readers, and Mobile/Smartphone Readers.

Based on Technique, the market was studied across Competitive Assays, Multiplex Detection Assays, and Sandwich Assays.

Based on Sample Type, the market was studied across Blood Samples, Saliva Samples, and Urine Samples.

Based on Application, the market was studied across Clinical Testing, Drug Development & Quality Testing, Food Safety & Environment Testing, and Veterinary Diagnostics. The Clinical Testing is further studied across Cardiac Marker Testing, Cholesterol Testing/Lipid Profiles, Drugs-of-Abuse Testing, Infectious Disease Testing, and Pregnancy & Fertility Testing. The Cardiac Marker Testing is further studied across BNP or NT-proBNP Testing, CK-MB Testing, D-Dimer Testing, Myoglobin Testing, Other Cardiac Markers, and Troponin I & T Testing. The Infectious Disease Testing is further studied across Covid-19, Hepatitis, Influenza, Mosquito-borne Diseases, Sexually Transmitted Infections, and Tuberculosis. The Sexually Transmitted Infections is further studied across Chlamydia, Gonorrhea, HIV, HPV, and Syphilis. The Pregnancy & Fertility Testing is further studied across Fertility Testing and Pregnancy Testing.

Based on End-User, the market was studied across Diagnostic Laboratories, Home Care Settings, Hospitals & Clinics, and Pharmaceutical & Biotechnology Companies.

Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of

COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Lateral Flow Assays Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Lateral Flow Assays Market, including Abbott Laboratories, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Chembio Diagnostic Systems, Inc., Danaher Corporation, F. Hoffman-La Roche Ltd., Hologic Inc., Merck KGaA, PerkinElmer Inc., Quidel Corporation, Siemens AG, and Thermo Fisher Scientific, Inc..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the United States Lateral Flow Assays Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Lateral Flow Assays Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Lateral Flow Assays Market?
4. What is the competitive strategic window for opportunities in the United States Lateral Flow Assays Market?
5. What are the technology trends and regulatory frameworks in the United States Lateral Flow Assays Market?
6. What is the market share of the leading vendors in the United States Lateral Flow Assays Market?
7. What modes and strategic moves are considered suitable for entering the United States Lateral Flow Assays Market?

Please Note: PDF & Excel + Online Access - 1 Year

Companies Mentioned

Abbott Laboratories, Inc.
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.
Chembio Diagnostic Systems, Inc.
Danaher Corporation
F. Hoffman-La Roche Ltd.
Hologic Inc.
Merck KGaA
PerkinElmer Inc.
Quidel Corporation
Siemens AG
Thermo Fisher Scientific, Inc.